SYK
ACCE-researchedStryker Corporation Common Stock
Healthcare · Medical Devices · NYSE · United States
$275.12-1.79%
Market cap $105.5BNext earnings 2026-10-29Updated Sep 18, 2026
FAIR VALUE · CONSENSUS
$275.12+0.0%
confidence-weighted across 4 of 6 models
Now $275.12
$275.12
$100.33$367.22
HoldBronze48
Price vs fair value
8.0% above
-7.4% to fair value
ACCE score
58
out of 100
Analysts
69% buy
32 covering
P/E
28.5x
forward 16.5x
1-year return
-27.2%
Dividend yield
1.24%
Unlock the ACCE read
INVESTOROverview
⚠ Investor warnings · 4 flags
- highHeavy insider sellingLast 10 transactions show $100.66M in sales and zero buys, signaling insiders are aggressively distributing shares at current prices.
- highTrailing vs forward P/E gapP/E of 38.2x versus forward P/E of 22.0x implies a massive earnings jump priced in; any miss could trigger sharp de-rating.
- moderateRevenue growth decelerationYoY revenue growth of only 2.6% is far below the 5-year CAGR of 14.8%, suggesting meaningful top-line slowdown.
- moderateSharp QoQ revenue declineQuarter-over-quarter revenue dropped 16.1%, a significant sequential deterioration worth monitoring for trend continuation.
Reports in 38 days, last quarter beat by 0.1%.
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
Price
-27.3% · 1Y
Valuation
INVESTORFull valuation engine INVESTOR FEATURE
Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.
- +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
- +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
- +Editable DCF workbench with saved scenarios
Quality
INVESTORQuality and conviction INVESTOR FEATURE
The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.
- +Conviction score breakdown and earnings-quality grade
- +Growth / value / quality / momentum component scores
- +90-day score history and score-threshold backtests
Analysts
Wall Street consensus
Bullish69% buy · 32 covering analysts
● Strong buy 13● Buy 9● Hold 9● Sell 1● Strong sell 0
Analyst intelligence INVESTOR FEATURE
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
- +Price-target low / average / high vs the current price, with implied upside
- +Forward revenue and EPS consensus by fiscal year
- +ACCE fair-value models lined up against the Street
Smart Money
PROSmart money tracking PRO FEATURE
Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.
- +Quarter-over-quarter institutional position changes
- +Recent open-market insider transactions
- +Active 13D activist filings and top holders
Compare
Where it sits vs peers
This stock Peer Peer median weaker → stronger
P/Ebetter than 50% of peers
low 17.5x28.5xhigh 52.5x
ROEbetter than 83% of peers
low 9%17%high 38%
Div yieldbetter than 50% of peers
low 0.0%1.2%high 3.1%
Algorithmic peers (6)
| Ticker | Company | Mcap | P/E | ROE | D/E | Yield | Quality | |
|---|---|---|---|---|---|---|---|---|
| MDT | Medtronic plc. Ordinary Shares | $117.8B | 22.7 | 10.7% | 0.56 | 3.1% | - | Compare |
| BSX | Boston Scientific Corporation Common Stock | $62.8B | 17.5 | 15.3% | 0.47 | 0.0% | - | Compare |
| ABT | Abbott Laboratories Common Stock | $177.6B | 33.2 | 10.6% | 0.25 | 2.4% | - | Compare |
| EW | Edwards Lifesciences Corporation Common Stock | $50.9B | 52.5 | 9.2% | 0.06 | 0.0% | - | Compare |
| SHL.DE | Siemens Healthineers | $48.4B | 19.2 | 12.2% | 0.61 | 2.6% | - | Compare |
| DXCM | DexCom Inc. Common Stock | $33.7B | 35.3 | 38.5% | 0.46 | 0.0% | - | Compare |
Sector report card
Where SYK ranks against its sector peers on each metric.
Computing percentiles…
News and Record
Reports in 38 days, last quarter beat by 0.1%.
Press releases mentioning this company
- Business Wire•Sep 10, 2026Dexcom Appoints Glenn Boehnlein to Board of Directors
- GlobeNewswire•Sep 9, 2026Pulmera Appoints Jared Slibeck Chief Commercial Officer
- GlobeNewswire•Sep 7, 2026Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery
7 more press releases · full archive on Investor+.INVESTOR
Ask anything, Pro feature
Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.
PRO
Recent performance
1 week
-0.2%
1 month
-19.1%
3 months
-10.6%
6 months
-18.0%
YTD
-21.7%
1 year
-27.2%
SEC filings
40 filings
September 2026
Sep 2
Form 4Insider transactionPeriod 2019-06-26
August 2026
Aug 26
Form 4Insider transactionPeriod 2026-08-21
Aug 20
Form 4Insider transactionPeriod 2026-08-18
37 more filings + AI summaries on Investor+.INVESTOR